ReviewCurrent cardiology reports2014
Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.
Review in Current cardiology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.Clinical cardiology · 2018Trial
- Diagnostic significance of cardiac bridging integrator 1 score in hospitalized patients with heart failure with preserved ejection fraction and its assessment of prognostic value for major adverse cardiac events.BMC cardiovascular disorders · 2025Article
- Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies.Journal of cardiovascular translational research · 2023Review
- Effects of elevation of ANP and its deficiency on cardiorenal function.JCI insight · 2022Article
- Left ventricular geometry, tissue composition, and residual stress in High Fat Diet Dahl-Salt sensitive rats.Experimental mechanics · 2021Article
- Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry.Clinical cardiology · 2019Article
- Article
- Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction.Expert review of cardiovascular therapy · 2018Review
- GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2018Article
- Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2017Article
- Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography.The international journal of cardiovascular imaging · 2017Review
- How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.Current cardiology reports · 2016Review
- Animal models of heart failure with preserved ejection fraction.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2016Review
- Heart Failure With Preserved Ejection Fraction: Prevention and Management.American journal of lifestyle medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major contributor to the development of heart failure with preserved ejection fraction (HFpEF). Our understanding of the epidemiology and pathophysiology of HFpEF in relation to hypertension has increased considerably in recent years. We now know that the pathophysiologic relationship between hypertension and HFpEF is more complex than simply the development of left ventricular hypertrophy and diastolic dysfunction and that there are multiple ways in which hypertension interacts with other comorbidities, the vasculature, and the heart to predispose to HFpEF. Although the treatment of HFpEF has been challenging, there is widespread agreement that control of systemic blood pressure is important in the management of these patients. Here we review the relationship between hypertension and HFpEF, focusing on (1) epidemiology and (2) pathophysiology of HFpEF in relation to hypertension; (3) prevention of HFpEF by controlling hypertension; and (4) established and novel therapeutics for hypertension in the setting of HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.